PD 146176, >=98% (HPLC), solid
Application
PD 146176 has been used to study its influence on ex vivo leukotriene B4 (LTB4) and lipoxin A4 (LXA4) secretion in adipose tissue.
Biochem/physiol Actions
15-Lipoxygenase inhibitor
PD 146176 blocks neuroprotectin D1 (NPD1) and eicosanoid synthesis by inhibiting the 5-lipoxygenase-1 (15-LOX-1) enzyme.
Features and Benefits
This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
| Colour | white to beige |
|---|---|
| Quality Level | 100 |
| InChI key | ZGOOPZVQMLHPFM-UHFFFAOYSA-N |
| InChI | 1S/C15H11NS/c1-3-7-13-10(5-1)12-9-17-14-8-4-2-6-11(14)15(12)16-13/h1-8,16H,9H2 |
| Manufacturer | SIGMA-ALDRICH |
| Form | solid |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
